XNW34017

· Evopoint Biosciences Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for XNW34017, covering 2026-01-08 to 2026-01-08. Get the full timeline:

Most recent: Clinical Trial Update: A Phase I/II Study to Evaluate XNW34017 in Patients With Advanced or Metastatic Solid Tumor [Phase 1, Phase 2]